Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06858319 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06858319 · ClinicalTrials.gov record · last posted 2026-08-17

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

StatusRecruiting
PhasePhase 3
Started2025-07-28
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.

Protocol amendment history 4 changes detected by DataLookout

2026-08-18
Trial sites expanded: 21 → 26 locations
2026-07-21
Trial sites expanded: 18 → 21 locations
2026-06-02
Trial sites expanded: 15 → 18 locations
2026-05-07
Trial sites expanded: 6 → 15 locations
Trial Details
NCT Number NCT06858319
Lead Sponsor Novartis Pharmaceuticals
Conditions Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
Enrollment 220 participants
Start Date 2025-07-28
Primary Completion 2031-06-25 (estimated)
Study Completion 2031-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-17